129 related articles for article (PubMed ID: 29581832)
1. AP-1 confers resistance to anti-cancer therapy by activating XIAP.
Wang Y; Wan GH; Wu YM; Wang HS; Wang HF; Zhang G; Lu LL; Li ZQ; Chan KY; Zhou Y; Cai SH; Qi YF; Du J
Oncotarget; 2018 Mar; 9(18):14124-14137. PubMed ID: 29581832
[TBL] [Abstract][Full Text] [Related]
2. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
[TBL] [Abstract][Full Text] [Related]
3. Histone deacetylase activity mediates acquired resistance towards structurally diverse HSP90 inhibitors.
Chai RC; Vieusseux JL; Lang BJ; Nguyen CH; Kouspou MM; Britt KL; Price JT
Mol Oncol; 2017 May; 11(5):567-583. PubMed ID: 28306192
[TBL] [Abstract][Full Text] [Related]
4. Functional and Transcriptional Characterization of Histone Deacetylase Inhibitor-Mediated Cardiac Adverse Effects in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
Kopljar I; Gallacher DJ; De Bondt A; Cougnaud L; Vlaminckx E; Van den Wyngaert I; Lu HR
Stem Cells Transl Med; 2016 May; 5(5):602-12. PubMed ID: 27034410
[TBL] [Abstract][Full Text] [Related]
5. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression.
Raha P; Thomas S; Thurn KT; Park J; Munster PN
Breast Cancer Res; 2015 Feb; 17(1):26. PubMed ID: 25848915
[TBL] [Abstract][Full Text] [Related]
6. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D
Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692
[TBL] [Abstract][Full Text] [Related]
7. Acquired vorinostat resistance shows partial cross-resistance to 'second-generation' HDAC inhibitors and correlates with loss of histone acetylation and apoptosis but not with altered HDAC and HAT activities.
Dedes KJ; Dedes I; Imesch P; von Bueren AO; Fink D; Fedier A
Anticancer Drugs; 2009 Jun; 20(5):321-33. PubMed ID: 19322073
[TBL] [Abstract][Full Text] [Related]
8. Activation of insulin-like growth factor receptor signaling mediates resistance to histone deacetylase inhibitors.
Kim JS; Lee SC; Min HY; Park KH; Hyun SY; Kwon SJ; Choi SP; Kim WY; Lee HJ; Lee HY
Cancer Lett; 2015 Jun; 361(2):197-206. PubMed ID: 25721083
[TBL] [Abstract][Full Text] [Related]
9. JNJ-26481585, a novel "second-generation" oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity.
Arts J; King P; Mariën A; Floren W; Beliën A; Janssen L; Pilatte I; Roux B; Decrane L; Gilissen R; Hickson I; Vreys V; Cox E; Bol K; Talloen W; Goris I; Andries L; Du Jardin M; Janicot M; Page M; van Emelen K; Angibaud P
Clin Cancer Res; 2009 Nov; 15(22):6841-51. PubMed ID: 19861438
[TBL] [Abstract][Full Text] [Related]
10. Histone deacetylase inhibitor reverses multidrug resistance by attenuating the nucleophosmin level through PI3K/Akt pathway in breast cancer.
Chen SY; Zheng XW; Cai JX; Zhang WP; You HS; Xing JF; Dong YL
Int J Oncol; 2016 Jul; 49(1):294-304. PubMed ID: 27211281
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
12. [Transcription of c-fos gene and DNA binding activity of transcription factor AP-1 increase upon differentiation of mouse F9 teratocarcinoma cells].
Chuĭkin IA; Lianguzova MS; Pospelov VA
Tsitologiia; 2004; 46(12):1080-90. PubMed ID: 15747838
[TBL] [Abstract][Full Text] [Related]
13. A novel HDAC inhibitor OBP-801 and a PI3K inhibitor LY294002 synergistically induce apoptosis via the suppression of survivin and XIAP in renal cell carcinoma.
Yamada T; Horinaka M; Shinnoh M; Yoshioka T; Miki T; Sakai T
Int J Oncol; 2013 Oct; 43(4):1080-6. PubMed ID: 23900601
[TBL] [Abstract][Full Text] [Related]
14. Antitumor effects of a novel histone deacetylase inhibitor NK-HDAC-1 on breast cancer.
Li ZH; Zhang XB; Han XQ; Feng CR; Wang FS; Wang PG; Shen J; Shi YK
Oncol Rep; 2013 Jul; 30(1):499-505. PubMed ID: 23624828
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase inhibitor induction of P-glycoprotein transcription requires both histone deacetylase 1 dissociation and recruitment of CAAT/enhancer binding protein beta and pCAF to the promoter region.
Kim SN; Kim NH; Lee W; Seo DW; Kim YK
Mol Cancer Res; 2009 May; 7(5):735-44. PubMed ID: 19435809
[TBL] [Abstract][Full Text] [Related]
16. High levels of X-linked Inhibitor-of-Apoptosis Protein (XIAP) are indicative of radio chemotherapy resistance in rectal cancer.
Flanagan L; Kehoe J; Fay J; Bacon O; Lindner AU; Kay EW; Deasy J; McNamara DA; Prehn JH
Radiat Oncol; 2015 Jun; 10():131. PubMed ID: 26071313
[TBL] [Abstract][Full Text] [Related]
17. DUSP1 expression induced by HDAC1 inhibition mediates gefitinib sensitivity in non-small cell lung cancers.
Lin YC; Lin YC; Shih JY; Huang WJ; Chao SW; Chang YL; Chen CC
Clin Cancer Res; 2015 Jan; 21(2):428-38. PubMed ID: 25593344
[TBL] [Abstract][Full Text] [Related]
18. Targeting histone deacetylase in cancer therapy.
Lin HY; Chen CS; Lin SP; Weng JR; Chen CS
Med Res Rev; 2006 Jul; 26(4):397-413. PubMed ID: 16450343
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibitor-induced cancer stem cells exhibit high pentose phosphate pathway metabolism.
Debeb BG; Lacerda L; Larson R; Wolfe AR; Krishnamurthy S; Reuben JM; Ueno NT; Gilcrease M; Woodward WA
Oncotarget; 2016 May; 7(19):28329-39. PubMed ID: 27078845
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase (HDAC) inhibitors and regulation of TRAIL-induced apoptosis.
Fulda S
Exp Cell Res; 2012 Jul; 318(11):1208-12. PubMed ID: 22366288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
